Purchase and successive supply of oncological drugs and various drugs, including dermatological drugs.

… Laws No. of Laws 2026, item 612, as amended). 3.3. The contracting authority shall not allow medicinal products authorised pursuant to Article 4(1)(b) CTMR to be offered. 1 and 2 of the Pharmaceutical Law Act of 6 September 2001 (Journal of Laws 2026, item 612, as amended). 3.4. in the case of medicinal products subject to reimbursement – with the exception of Part No 25 – they met the requirements set out in the Act of 12 May 2011 on the reimbursement of medicines, foodstuffs intended for particular nutritional uses and medical devices (Journal of Laws No. of Laws 2026, item 253, as amended), to the extent applicable to the subject-matter of the contract. The Contracting Authority reserves the right to require the Contractor, at any stage of the procedure, to submit documents confirming compliance with the requirements set out in point 3.2 above, in particular documents confirming the authorisation of the medicinal products offered for marketing in the territory of the Republic of Poland, including temporary authorisation pursuant to Art. 8 of the Act of 6 September 2001 Pharmaceutical Law approved by the Minister of Health, translated leaflet, SmPC of the offered medicinal product and documents confirming the compliance of the offered items of the order with the requirements of applicable law. 3.5. Note to point 3.4: The provisions of paragraph 3.4 and this note do not apply to Part 25. Lot 25 is not covered by the Medicines Programme; the medicinal product in this part is intended for use under Emergency Access to Drug Technologies (RDTL). For the remaining parts, if it is found that the chemical substance in the dose and form indicated in the tender specification is included in the current Notice of the Minister for Health on the list of reimbursed medicines, foodstuffs intended for particular nutritional uses and medical devices – Annex B and/or C, and the medicinal product offered is not indicated there, the tender will be rejected. The offer will also be rejected if the price of the offered medicinal product is higher than the official price indicated in the current announcement of the Minister of Health on the list of reimbursed medicines, foodstuffs for particular nutritional uses and medical devices, if the official price applies to the given medicinal product. 4 . The scope of the contract includes the delivery of the items of the order in the quantities specified in the Price and Offer Forms for the period of: for Parts No 1 to No 51, 12 months from the date of conclusion of the contract. 5. The subject of the contract within the scope of Parts No. 1 to No. 51 will be carried out in the form of successive deliveries for a period of 12 months from the date of conclusion of the contract. 6. In the event that during the term of the contract the subject of the contract is not fully realized in relation to Lots No. 1 to No. 51, the Ordering Party reserves the right to extend the term of the contract. The change of the term of the contract will take place by means of a written annex signed by the Parties. The Contracting Authority shall inform the Contractor of its intention to extend the duration of the contract before the expiry of the period for which it was concluded.